ReviewAnnals of medicine2026
Circadian rhythms in major depressive disorder: mechanistic insights and therapeutic frontiers.
Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor Depressive Disorder (MDD) has emerged as a leading cause of disability worldwide, affecting over 264 million people. Recent evidence reveals that disruption of circadian rhythms may be fundamental to MDD pathophysiology, opening new avenues for therapeutic intervention.
methodsThis review synthesizes current understanding of the intricate relationship between circadian system disruption and MDD, highlighting molecular mechanisms and clinical implications. We examine evidence from genetic studies, clinical observations, and therapeutic trials.
resultsPatients with MDD exhibit profound alterations in circadian-regulated processes, including sleep-wake cycles, diurnal mood patterns, and metabolic functions. Genetic studies have identified variants in core clock genes, particularly CLOCK, TIMELESS, and CRY1, that correlate with both circadian disruption and MDD susceptibility. These genetic insights, combined with evidence of dysregulated hypothalamus-pituitary-adrenal axis function and abnormal melatonin signaling, suggest that circadian dysfunction may be causal in MDD pathogenesis rather than merely symptomatic.
conclusionsEmerging chronotherapeutic approaches, such as light therapy, sleep interventions, and targeted pharmacology, show significant potential for improving depressive symptoms. Personalized circadian-based treatments, guided by genetic and molecular markers, could transform MDD care. Advancing our understanding of the circadian-depression connection offers a promising path to revolutionizing treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.